2004
DOI: 10.1158/1078-0432.ccr-04-1169
|View full text |Cite
|
Sign up to set email alerts
|

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers

Abstract: Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are active in cancer therapy. Mechanisms engaged during these clinical responses need to be determined. We reported previously that epidermal growth factor stimulation markedly increased cyclin D1 protein expression in human bronchial epithelial (HBE) cells, and this was opposed by chemoprevention with alltrans-retinoic acid. The current study sought to determine whether the EGFR TKI erlotinib repressed cyclin D1 protein express… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

9
92
0

Year Published

2005
2005
2017
2017

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 88 publications
(101 citation statements)
references
References 21 publications
9
92
0
Order By: Relevance
“…In preclinical studies, erlotinib, given orally at 92 mg/kg, did not produce marked tumor penetration, achieving only a tumor/plasma ratio of 0.4 in mouse HN5 xenografts at 6 hours after dosing (25), compared with a gefitinib tumor/plasma ratio of 5 to 14 across a range of mouse tumor xenografts. A similar tumor/plasma profile has also been observed in a recent clinical study, where the mean concentration of erlotinib in lung or larynx tumors (2.9 Amol/L) of cancer patients treated daily with erlotinib (150 mg) for 9 days was about 55% of the mean plasma concentration (26). Although based on data from only four subjects, this limited distribution profile was consistent with the much lower volume of distribution (136 L) observed with erlotinib in man (27).…”
Section: Discussionsupporting
confidence: 83%
“…In preclinical studies, erlotinib, given orally at 92 mg/kg, did not produce marked tumor penetration, achieving only a tumor/plasma ratio of 0.4 in mouse HN5 xenografts at 6 hours after dosing (25), compared with a gefitinib tumor/plasma ratio of 5 to 14 across a range of mouse tumor xenografts. A similar tumor/plasma profile has also been observed in a recent clinical study, where the mean concentration of erlotinib in lung or larynx tumors (2.9 Amol/L) of cancer patients treated daily with erlotinib (150 mg) for 9 days was about 55% of the mean plasma concentration (26). Although based on data from only four subjects, this limited distribution profile was consistent with the much lower volume of distribution (136 L) observed with erlotinib in man (27).…”
Section: Discussionsupporting
confidence: 83%
“…Trough, peak, and average steady-state plasma concentrations in treated patients reach 9.7, 15, and 11 Amol/L, respectively. Therefore, responses at the 10 Amol/L concentration lie within the window of clinical relevance (25,36,37). Moreover, growth inhibition by erlotinib for sensitive cell lines is dose dependent (24).…”
Section: Resultsmentioning
confidence: 96%
“…The prevalence of the GG genotype in cyclin D1 overexpression seems to be about 30%. Dual targeting of cyclin D1 with bexarotene and erlotinib potentially will overcome the retinoic acid/rexinoid limitation in patients with this common polymorphism because erlotinib can transcriptionally repress cyclin D1 expression (17). Cyclin D1 is a very relevant prevention target, with frequent overexpression, in premalignant lung carcinogenesis, as shown, for example, by preclinical and clinical results of the Dmitrovsky group (10,18).…”
Section: Introductionmentioning
confidence: 99%